Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620662
Title:
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Authors:
Sydes, M. R. [et al]; Sheehan, Denise
Abstract:
Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative data of SOC+AAP vs SOC+DocP.
Citation:
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 2018 Ann. Oncol.
Publisher:
Oxford Journals
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology
Issue Date:
26-Feb-2018
URI:
http://hdl.handle.net/11287/620662
DOI:
10.1093/annonc/mdy072
PubMed ID:
29529169
Additional Links:
https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdy072
Type:
Journal Article
Language:
en
ISSN:
1569-8041
Appears in Collections:
Oncology; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSydes, M. R. [et al]en
dc.contributor.authorSheehan, Deniseen
dc.date.accessioned2018-05-03T13:20:03Z-
dc.date.available2018-05-03T13:20:03Z-
dc.date.issued2018-02-26-
dc.identifier.citationAdding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 2018 Ann. Oncol.en
dc.identifier.issn1569-8041-
dc.identifier.pmid29529169-
dc.identifier.doi10.1093/annonc/mdy072-
dc.identifier.urihttp://hdl.handle.net/11287/620662-
dc.description.abstractAdding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative data of SOC+AAP vs SOC+DocP.en
dc.language.isoenen
dc.publisherOxford Journalsen
dc.relation.urlhttps://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdy072en
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncologyen
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleAdding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.en
dc.typeJournal Articleen
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical Oncologyen
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.